MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)

CompletedOBSERVATIONAL
Enrollment

136

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Ischemic Heart DiseaseCoronary Microvascular DiseaseAnginaMyocardial Ischemia
Interventions
DEVICE

CardioFlux

The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity.

Trial Locations (8)

32610

University of Florida, Division of Cardiovascular Medicine, Gainesville

41017

Saint Elizabeth Medical Center, Edgewood

44195

Cleveland Clinic, Cardiovascular Medicine Research, Cleveland

45219

The Christ Hospital, Cincinnati

48236

Ascension St. John Hospital, Detroit

55905

Mayo Clinic, Cardiovascular Research, Rochester

64111

St. Luke's Health System, Cardiovascular Research, Kansas City

07042

Hackensack Meridian Mountainside Medical Center, Montclair

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genetesis Inc.

INDUSTRY

NCT06212466 - MCG as a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2) | Biotech Hunter | Biotech Hunter